Providence and Regence Reach Agreement

January 15, 2024 Providence Oregon News Team

Share this Article
Facebook
Twitter
LinkedIn

10 a.m., Jan. 15, 2024

NEWS RELEASE: PROVIDENCE AND REGENCE REACH AGREEMENT TO CONTINUE CARE DELIVERY SERVICES TOGETHER

We are pleased to announce that Providence and Regence have worked throughout the weekend and have reached agreement for a new contract. As we finalize our work on that new contract, Providence has rescinded its contract termination. This means that all Providence patients with Regence health insurance will continue to have in-network access to care at Providence facilities and clinics.

We are grateful for Regence’s acknowledgement of our need to meet rising costs and compensate our caregivers, and we look forward to working in continued partnership and collaboration with Regence to serve our patients and communities with world-class health care services.

Studies address need for more treatment options in endometrial cancer and AML

New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, ...

Documentary film features Providence patients, researchers in pursuit of revolutionary cancer therapy

"Within Reach: The Fight to Finish Cancer" follows patient participants and teams of researchers and clinic...

Other content in this Stream

Celebrating World Immunology Day

Providence and Regence Reach Agreement

Previous Article

Next Article

Other content in this Stream

Providence Cancer Institute researcher shares her journey to immunology and the advice she has for those seeking a career in cancer research.

Jennifer Burrows, RN, has been chosen to serve as the chief executive of Providence Oregon.

Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.

In recognition of National Social Work Month, Darlene Corral, LCSW, shares a little insight into the importance of oncology social workers.

In honor of National Nutrition Month® Alyssa George, MA, RDN, program manager at Oncology Nutrition, Providence Cancer Institute, talks about the important connection between cancer and nutrition.

In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.

Please revert to normal e-prescribing workflows and stop using paper prescriptions.

Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.

The Food and Drug Administration has approved an adoptive cell therapy for adult patients with melanoma that has spread to other parts of the body (metastatic).

Supporting thousands of patients experiencing food insecurity, a converted space at Providence Gateway Internal Medicine clinic is filled with fresh fruits and vegetables, meat, milk, eggs and more.

Jamie Zilverberg, MSN, FNP, AOCNP, receives the prestigious 2024 Values in Action Award, the highest honor given at Providence St. Joseph Health.

In honor of International Day of Women and Girls in Science we highlight a researcher at Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute.

Providence registered dietitian Christina Speaks, MS, RDN, LD, shares valuable information about food and common cancer myths.

New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy

"Within Reach: The Fight to Finish Cancer" follows patient participants and teams of researchers and clinicians at Providence Cancer Institute working to create a living drug for incurable cancers.

New articles co-authored by Dr. Rachel Sanborn feature amivantamab studies for people with NSCLC.

The Oregon Health Authority has selected the Portland, Oregon-based Center for Outcomes Research & Education (CORE) to create an evaluation design for Oregon's 2022-2027 1115 Medicaid waiver.

Highlights from 2023 events, achievements and advancements at Providence Cancer Institute.

Providence hematology oncologist and outdoors enthusiast Eric C. Anderson, M.D., shares his love of the Pacific Northwest and his philosophy of care for patients.

A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.